UnitedHealth Group (UNH 1.99%) and Johnson & Johnson (JNJ -0.04%) are two of the largest healthcare companies in the world. One is focused on health insurance, while the other makes medical devices and pharmaceuticals. They both pay dividends and have generated good returns for investors over the years. But which one is the best option for growth-oriented investors today?UnitedHealth's endless pursuit of acquisitions could make it an underrated growth investmentA health insurance company may not attract man ...

Investing in the stock market isn’t without the risks, but what if you could generate extra income from your investment? If you are a risk-averse investor like me and want to build a retirement portfolio, dividend stocks with consistent cash flow will appeal to you. You can achieve your goal of generating consistent income while you enjoy capital appreciation. If you invest in the right stocks, you can also cover expenses throughout the year. With the ongoing earnings season, several companies will hike the ...

US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People's Action, protesting pharmaceutical companies' lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021.The CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders announced Friday, as ...

Johnson & Johnson (JNJ) reported fourth-quarter and full-year 2024 results on Jan 23. The drug and medical devices giant beat the Zacks Consensus Estimate for both earnings as well as sales in the fourth quarter.In August, J&J completely separated its Consumer Health business into a newly listed company called Kenvue (KVUE) , which now operates as a separate and fully independent company.After completion of the exchange offer, J&J now has a 9.5% stake (approximately 180 million shares) in Kenvue’s common st ...

Buying dividend-paying stocks to hold for long periods is a relatively simple method for building wealth. That said, picking stocks most likely to maintain and raise their dividend payouts isn't always so straightforward.Johnson & Johnson (JNJ -0.53%) and Verizon Communications (VZ -2.25%) are two legendary dividend payers that recently announced results from the last three months of 2023. Let's look at their performances in light of their competitive advantages to see which is likely to deliver more divide ...

Dividend Stocks Overview - Stocks have outperformed other asset classes over the past century, with equities beating gold by 5.6% annually, housing prices by 6.6%, Treasuries by 6.8%, and oil by 8.4% annually [1] - Dividend stocks have historically outperformed non-dividend payers with less risk, making them a strong choice for long-term investment [1] - Between 1973 and 2022, dividend-growing stocks returned over 10%, while stocks that cut dividends lost money [1] LVMH Moet Hennessy Louis Vuitton (LVMUY) - LVMH owns 75 luxury brands across various categories, including Louis Vuitton, Dior, Fendi, and Sephora [2] - The company enjoys gross margins of almost 70% and operating margins above 25% [2] - LVMH's customer base represents the top 5% of luxury spenders, accounting for 40% of global luxury sales [3] - The company pays dividends twice a year, with a 16% annual growth rate over the past five years and 13% over the last decade [3] - Free cash flow (FCF) has grown exponentially, supporting its dividend payouts [3] Johnson & Johnson (JNJ) - Johnson & Johnson focuses on high-margin pharmaceutical drugs, which make up 65% of its total revenue [5] - The company has a portfolio of billion-dollar therapies, including Stelara, Tremyfa, Darzalex, and Simponi [5] - Revenue is forecast to grow 7-8% annually, with adjusted profits growth of 12-13% [5] - Johnson & Johnson spun off its consumer products business into Kenvue, allowing it to focus more on healthcare [5] - The company has paid dividends every year since 1944 and has raised its payout for 61 consecutive years [6] - It currently yields a 2.8% annual dividend with a payout ratio of 35%, indicating room for future growth [6] Lowe's (LOW) - Lowe's has delivered a 511% total return since 2014, outperforming the S&P 500's 210% return [7] - The company has increased its dividend at a compounded annual rate of 20% over the last decade and has raised it for 60 consecutive years [7] - Lowe's has a low payout ratio of 34%, supported by strong free cash flow of $11 per share compared to an annual dividend of $4.38 per share [7][8] - The company is the largest retailer of appliances with a 28% market share, ahead of Home Depot (23%) and Best Buy (14%) [8] - Lowe's business is resilient during housing market declines, as homeowners continue to invest in home improvement projects [8]

Sundry Photography Johnson & Johnson (NYSE:JNJ) reported Q4 earnings on January 23 that exceeded expectations, reaffirming guidance for FY24. The company recently spun off its consumer health subsidiary, Kenvue (KVUE), in 2023, redirecting its focus toward pharmaceuticals and medical devices. I am initiating coverage with a 'Buy' rating and a fair value target of $180 per share. 5-7% Growth in their Pharma Business JNJ stands as the second-largest pharmaceutical company globally, presenting a diverse po ...

OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its role in the opioid addiction crisis.“They knew what the harm was. They did it anyway,” Attorney General Bob Ferguson told reporters Wednesday.The attorney general’s announcement came as opioid overdose deaths more than doubled from 2019 to 2022, with 2,048 deaths recorded in 2022, according to the most recent ...

Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding quarter in 2022. The pharmaceutical giant disclosed a net income of $4.13 billion, a rise from the $3.23 billion reported in the previous year. During their most recent quarterly earnings call on Tuesday (Jan. 23), J&J executives said the earnings growth in the first half of the year would be positively influence ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...